Stemline Therapeutics (STML) Upgraded to “Hold” by ValuEngine

Stemline Therapeutics (NASDAQ:STML) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 14th. BidaskClub cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. Finally, Zacks Investment Research cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $31.33.

Stemline Therapeutics (STML) opened at $14.35 on Friday. Stemline Therapeutics has a one year low of $7.30 and a one year high of $18.75. The stock has a market cap of $433.51, a P/E ratio of -4.88 and a beta of -0.07.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.26). Stemline Therapeutics had a negative net margin of 4,689.63% and a negative return on equity of 94.70%. equities analysts expect that Stemline Therapeutics will post -2.83 earnings per share for the current fiscal year.

In related news, CEO Ivan Bergstein sold 3,820 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $15.80, for a total value of $60,356.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Kenneth Hoberman sold 11,026 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $17.43, for a total transaction of $192,183.18. The disclosure for this sale can be found here. Insiders sold 156,418 shares of company stock valued at $2,628,131 in the last quarter. 16.70% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Northern Trust Corp increased its holdings in shares of Stemline Therapeutics by 18.0% in the second quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock valued at $2,529,000 after purchasing an additional 41,898 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Stemline Therapeutics by 74.9% in the second quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock valued at $1,108,000 after purchasing an additional 51,578 shares in the last quarter. Lyon Street Capital LLC increased its holdings in shares of Stemline Therapeutics by 331.1% in the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after purchasing an additional 415,867 shares in the last quarter. Cowen Inc. acquired a new stake in shares of Stemline Therapeutics in the third quarter valued at approximately $420,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Stemline Therapeutics in the fourth quarter valued at approximately $374,000. 52.00% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3299111/stemline-therapeutics-stml-upgraded-to-hold-by-valuengine.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

KingN Coin  Price Up 28.5% This Week
KingN Coin Price Up 28.5% This Week
LiteDoge Market Capitalization Tops $2.71 Million
LiteDoge Market Capitalization Tops $2.71 Million
FujiCoin  Trading 33.1% Higher  Over Last 7 Days
FujiCoin Trading 33.1% Higher Over Last 7 Days
Analysts Expect Casella Waste Systems  Will Post Earnings of -$0.01 Per Share
Analysts Expect Casella Waste Systems Will Post Earnings of -$0.01 Per Share
Iron Mountain  Issues  Earnings Results
Iron Mountain Issues Earnings Results
Ellie Mae  Issues  Earnings Results
Ellie Mae Issues Earnings Results


© 2006-2018 Ticker Report. Google+.